Quick Answer
L-Arginine Cardiovascular Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: More importantly, this BP elevation was closely associated with adverse outcomes, with cardiovascular mortality risk increasing by 21% for every 10 mmHg increase in SBP, and winter cardiovascular mortality rates being 41% higher than those in summer (Yang et al. ).
Key Takeaways
- 01More importantly, this BP elevation was closely associated with adverse outcomes, with cardiovascular mortality risk increasing by 21% for every 10 mmHg increase in SBP, and winter cardiovascular mortality rates being 41% higher than those in summer (Yang et al. ). [Luo Ping (2026)]
- 02Given that cold environment‐induced BP elevation is one of the important modifiable risk factors for CVD (Gu et al. ; Yokoyama et al. ), targeted interventions to control elevated BP during cold weather are particularly crucial (Xu et al. ,). [Luo Ping (2026)]
- 03On the other hand, cold can upregulate L‐type calcium channels (Saad et al. ), induce oxidative stress (Briones and Touyz ; Martarelli et al. ), and impair endothelial NO bioavailability (Ding et al. ; Lanzinger, Breitner, et al. ), resulting in impaired vasodilatory function and increased BP. [Luo Ping (2026)]
- 04BP CI CPT CVD DBP eNOS mmHg NO PICOS PRISMA PROSPERO RCT RoB 2 SBP WMD 2024 2025 2020 2020 2023 2017 2022 2024 2022 2017 2015 2023 2019 2024 2017 2015 2018 2014 2019 2024 2015 2020 Cardiovascular disease (CVD) represents the leading cause of the global disease burden (Chong et al. ; GBD 2021 ASEAN Cardiovascular Diseases Collaborators ; Roth et al. ). [Luo Ping (2026)]
The current Migaku evidence database contains 2 reusable source documents for L-Arginine Cardiovascular Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts.
- More importantly, this BP elevation was closely associated with adverse outcomes, with cardiovascular mortality risk increasing by 21% for every 10 mmHg increase in SBP, and winter cardiovascular mortality rates being 41% higher than those in summer (Yang et al. ). [Luo Ping (2026); evidence level 1]
- Given that cold environment‐induced BP elevation is one of the important modifiable risk factors for CVD (Gu et al. ; Yokoyama et al. ), targeted interventions to control elevated BP during cold weather are particularly crucial (Xu et al. ,). [Luo Ping (2026); evidence level 1]
- On the other hand, cold can upregulate L‐type calcium channels (Saad et al. ), induce oxidative stress (Briones and Touyz ; Martarelli et al. ), and impair endothelial NO bioavailability (Ding et al. ; Lanzinger, Breitner, et al. ), resulting in impaired vasodilatory function and increased BP. [Luo Ping (2026); evidence level 1]
- BP CI CPT CVD DBP eNOS mmHg NO PICOS PRISMA PROSPERO RCT RoB 2 SBP WMD 2024 2025 2020 2020 2023 2017 2022 2024 2022 2017 2015 2023 2019 2024 2017 2015 2018 2014 2019 2024 2015 2020 Cardiovascular disease (CVD) represents the leading cause of the global disease burden (Chong et al. ; GBD 2021 ASEAN Cardiovascular Diseases Collaborators ; Roth et al. ). [Luo Ping (2026); evidence level 1]
- This is based on evidence from numerous randomized studies showing that treating patients with these BP values leads to benefits in the prevention and management of systemic diseases [,]. [Abate Federico (2026); evidence level 2]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources